22 November 2021 : Clinical Research
Serum Beta-2 Microglobulin: A Possible Biomarker for Atrial Fibrillation
Bangying Zhang1ABCDEF, Xinpei Chen1BCDE, Xiaofeng Mu1BDE, Enzhao Liu1AB, Tong Liu1BE, Gang Xu1BC, Qiankun Bao1CDE, Guangping Li1AFG*DOI: 10.12659/MSM.932813
Med Sci Monit 2021; 27:e932813
Table 4 Clinical and laboratory characteristics of patients in the research.
| Atrial fibrillation n=57 | |
|---|---|
| Age, year | 64.12±8.97 |
| Male gender, n (%) | 33 (57.9%) |
| Heart rate, bpm/min | 72.16±17.68 |
| Systolic blood pressure, mmHg | 131.16±16.31 |
| Diastolic blood pressure, mmHg | 79.21±9.79 |
| CHADSVASc | 2.21±1.29 |
| Hypertension, n (%) | 33 (57.9%) |
| Diabetes mellitus, n (%) | 12 (21.1%) |
| Previous stroke, n (%) | 8 (14.0%) |
| Use of statins | 23 (40.4%) |
| Use of ACEI/ARB | 21 (36.8%) |
| eGFR, mL/min | 109.78±26.69 |
| LAD (mm) | 41.16±4.77 |
| LVEDD (mm) | 47.65±4.11 |
| LVESD (mm) | 28.27±4.88 |
| LVPWT (mm) | 9.11±1.37 |
| RVAWT (mm) | 3.45±0.57 |
| RVEDD (mm) | 21.06±2.12 |
| PAD (mm) | 22.02±2.46 |
| LVEF (mm) | 62.07±5.33 |
| eGFR – estimated glomerular filtration rate; LAD – left atrial anteroposterior diameter; LVEDD – left ventricular end-diastolic diameter; LVESD – left ventricular end-systolic diameter; LVPWT – left ventricular posterior wall thickness; RVAWT – right ventricular anterior wall thickness; RVEDD – right ventricular end-diastolic diameter; PAD – pulmonary artery diameter; LVEF – left ventricular ejection fraction. Data are means±standard deviation (SD). | |